Although there is a great potential to treat melanoma with MCL1 inhibitors in combination with ICIs, the current generation of MCL1 inhibitors are not suitable for use in the clinic due to dose-dependent cardiac toxicity [58]. Here, MCL1 is linked to melanoma.